HK Stock Market Move | REMENGE (09995) surged over 6%, with 25-year shareholders' net profit reaching 709 million yuan. Institutions expect its cash reserves to increase significantly.

REMEGEN (09995) rose more than 6%, at the time of publication, it rose 6.44%, to 81.75 Hong Kong dollars, with a turnover of 170 million Hong Kong dollars. On the news front, recently, REMEGEN released its 2025 annual performance report, with the company achieving total operating revenue of 3.251 billion Chinese Yuan, an increase of 89.36% year-on-year; net profit attributable to owners of the parent company was 709 million Chinese Yuan, turning losses into profits year-on-year; and basic earnings per share of 1.29 Chinese Yuan. The announcement stated that the increase in operating income was mainly due to an increase in sales of injection of pertuzumab and injection of vedolizumab, leading to an increase in sales revenue; in addition, the company granted Vor Biopharma Inc. exclusive developmental and commercialization rights for pertuzumab globally except for the Greater China region, leading to a substantial increase in technology licensing revenue. Nomura released a research report predicting that REMEGEN's gross profit margin is expected to increase by 5.4 percentage points to 94.4% annually this year, mainly benefiting from the increase in drug gross profit margin and the higher proportion of high-margin cooperation income. Due to a significant increase in cash reserves, the company's operating expenses are expected to increase by 28% to 3.5 billion Chinese Yuan annually, reversing the cost-saving trend from last year. Specifically, research and development expenses and sales expenses are expected to be 1.6 billion Chinese Yuan each, used for sponsoring new molecular research and clinical trials, as well as enhancing drug sales.